64

Lenalidomide

64 Publications Verification

Cat. No.: HY-A0003

CAS No.: 191732-72-6

Synonyms: CC-5013

Target:

Molecular Glues Ligands for E3 Ligase IKZF Family Casein Kinase Apoptosis Pyroptosis MDM-2/p53 TNF Receptor

Research Areas:

Cardiovascular Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer

Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8 ⁺ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

64

Lenalidomide hemihydrate

64 Publications Verification

Cat. No.: HY-A0003B

CAS No.: 847871-99-2

Synonyms: CC-5013 hemihydrate

Target:

Molecular Glues Ligands for E3 Ligase IKZF Family Casein Kinase Apoptosis Pyroptosis MDM-2/p53 TNF Receptor

Lenalidomide hemihydrate (CC-5013 hemihydrate) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide hemihydrate induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide hemihydrate promotes IL-2 release and effector functions of CD8 ⁺ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide hemihydrate can be used in research related to hematological malignancies, acute liver failure and acute kidney injury .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

61

GSK484

61 Cited Publications

Cat. No.: HY-123606

CAS No.: 1652629-23-6

Target:

Protein Arginine Deiminase MHC

Research Areas:

Cardiovascular Disease Inflammation/Immunology

GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8 ⁺ T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

8

Lomitapide mesylate

8 Cited Publications

Cat. No.: HY-14668

CAS No.: 202914-84-9

Purity: 99.57%

Synonyms: AEGR-733 mesylate; BMS-201038 mesylate

Target:

Microsomal Triglyceride Transfer Protein (MTP) mTOR LDLR Autophagy Apoptosis

Research Areas:

Cardiovascular Disease Neurological Disease Metabolic Disease Cancer

Lomitapide (AEGR-733; BMS-201038) mesylate is an orally active microsomal triglyceride transfer protein (MTP) inhibitor and a selective mTORC1 inhibitor with lipid-lowering activity and BBB permeability. Lomitapide mesylate significantly reduces plasma LDL levels by blocking the assembly and secretion of very-low-density lipoprotein (VLDL). Lomitapide mesylate inhibits mTORC1 in an ATP-dependent manner, thereby inducing AMPK-independent autophagic cell death and suppressing cancer cell growth and apoptosis. Lomitapide mesylate also enhances tumor infiltration of CD8 ⁺ T cells. In addition, Lomitapide mesylate inhibits HDAC, improves endothelial function, effectively alleviates vascular inflammation and oxidative stress, and exerts neuroprotective effects in a cerebral ischemia/reperfusion injury model. Lomitapide mesylate can be used in research on related diseases such as colorectal cancer, breast cancer, melanoma, ischemic stroke, and familial hypercholesterolemia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

Anti-Mouse CD8a Antibody (53-6.7)

4 Cited Publications

Cat. No.: HY-P99129

Anti-Mouse CD8a Antibody (53-6.7) is an anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat. Anti-Mouse CD8a Antibody (53-6.7) binds to CD8αβ stabilizes a conformation with a higher affinity for interaction with MHC class I. Anti-Mouse CD8a Antibody (53-6.7) induces the phosphorylation and activation of TCR proximal signaling pathway components Lck and ZAP70 in polyclonal memory T cells. Anti-Mouse CD8a Antibody (53-6.7) depletes CD8+ T cells and neutralizes cytokine in mice .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

Soquelitinib

3 Cited Publications

Cat. No.: HY-150298

CAS No.: 2226636-04-8

Purity: 99.71%

Synonyms: CPI-818

Target:

Itk

Research Areas:

Inflammation/Immunology Cancer

Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 ⁺ cells that possess enhanced T effector function .

Compare

loading...